Fifth Third Bancorp
VRDN icon

Fifth Third Bancorp’s Viridian Therapeutics VRDN Stock Holding History

Fifth Third Bancorp’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.97K Buy
+306
New +$9.09K ﹤0.01% 3819

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fifth Third Bancorp's VRDN Position: Q1 2026 in Review

Fifth Third Bancorp opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 306 shares worth $5.97K. The stake represents ﹤0.01% of the portfolio and ranks #3819 among its holdings.

225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Fifth Third Bancorp held 306 shares of Viridian Therapeutics worth $5.97K as of Q1 2026.
  • Viridian Therapeutics was a new Fifth Third Bancorp position in Q1 2026.
  • Viridian Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #3819 holding.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.